Meldonium and Telmisartan Interaction: Synergistic | Peptide Database

Join others researching RU-58841 — share findings, ask questions, and learn from real experiences RU-58841 is a non-steroidal anti-androgen originally developed by Roussel Uclaf (later Hoechst Marion Roussel) in the 1970s-80s for topical treatment of androgen-dependent conditions including acne and androgenetic alopecia. It works by competitively binding to androgen receptors at the hair follicle, blocking the effects of dihydrotestosterone (DHT) locally without significantly reducing systemic androgen levels. Development was abandoned after Phase II clinical trials, and the compound was never submitted for regulatory approval. Despite this, RU-58841 has developed a substantial following in the hair loss community, where users source it as a raw research chemical and prepare their own topical solutions. Its extremely short systemic half-life means that even if absorbed through the skin, it is rapidly metabolized, limiting systemic anti-androgenic effects. However, the lack of completed clinical trials means its long-term safety profile remains unknown. RU-58841 functions as a competitive antagonist of the androgen receptor (AR). When applied topically to the scalp, it penetrates the skin and binds directly to androgen receptors in dermal papilla cells of hair follicles, preventing dihydrotestosterone (DHT) and testosterone from activating those receptors. This is fundamentally different from 5-alpha reductase inhibitors like finasteride, which reduce DHT production systemically. RU-58841 does not lower DHT or testosterone levels at all; it simply blocks their action at the receptor level in the tissue where it is applied. The compound has a very high binding affinity for the androgen receptor but an extremely short systemic half-life of roughly one hour due to rapid hydrolysis of its amide bond in the bloodstream. This pharmacokinetic profile is intentional: it confines the anti-androgenic activity to the scalp while minimizing the risk of systemic side effects such as sexual dysfunction or hormonal disruption. Animal studies in hamster flank organ and stumptail macaque models demonstrated significant local anti-androgenic effects, including hair regrowth and inhibition of androgen-dependent sebaceous gland activity, without measurable systemic anti-androgenic effects at therapeutic topical doses.

Join others researching Doxepin — share findings, ask questions, and learn from real experiences Doxepin is a tricyclic compound with a remarkably dose-dependent pharmacological profile. At higher doses (75-300 mg), it functions as a traditional tricyclic antidepressant (TCA) with activity across multiple neurotransmitter systems. However, at ultra-low doses (3-6 mg), doxepin acts almost exclusively as a highly selective histamine H1 receptor antagonist, making it one of the most targeted sleep maintenance agents available. This ultra-low dose formulation was approved by the FDA in 2010 under the brand name Silenor specifically for the treatment of insomnia characterized by difficulty with sleep maintenance. The distinction between high-dose and ultra-low dose doxepin is critical: at 3-6 mg, the drug avoids the anticholinergic, noradrenergic, and serotonergic side effects that characterize tricyclic antidepressants, resulting in a remarkably clean side effect profile. For biohackers and those seeking a non-habit-forming sleep aid, ultra-low dose doxepin offers a compelling option -- it does not produce dependence, does not cause rebound insomnia upon discontinuation, and maintains efficacy with long-term use. Unlike benzodiazepines and Z-drugs, it carries no abuse potential and is not a scheduled substance. At ultra-low doses (3-6 mg), doxepin's mechanism of action is dominated by potent and selective antagonism of the histamine H1 receptor. Doxepin has one of the highest affinities for the H1 receptor of any known compound (Ki approximately 0.17 nM), which means that even at very low plasma concentrations, it effectively blocks histaminergic wakefulness signaling. The histamine system is a key component of the ascending arousal pathway -- histaminergic neurons in the tuberomammillary nucleus of the hypothalamus fire during wakefulness and become quiescent during sleep. By blocking H1 receptors, ultra-low dose doxepin reduces this wake-promoting signal, particularly during the latter half of the night when endogenous histamine levels naturally begin to rise, which is why it is especially effective for sleep maintenance insomnia. At these low doses, doxepin has negligible affinity for muscarinic, adrenergic, and serotonergic receptors, which explains the absence of anticholinergic side effects (dry mouth, constipation, urinary retention) and cardiovascular effects that plague higher-dose TCA use. At antidepressant doses (75-300 mg), doxepin additionally inhibits reuptake of serotonin and norepinephrine and blocks muscarinic, alpha-1 adrenergic, and 5-HT2 receptors, producing a much broader and less selective pharmacological profile.